Norman James Lacayo, MD is a Pediatrician - Pediatric Hematology-Oncology, Pediatrician - General practicing in Palo Alto, CA
He has not yet shared a personalized biography with Doctor.com.
University | Degree | Focus | Graduated |
---|---|---|---|
University of Ca, San Francisco, School of Medicine, San Francisco Ca | Other Degree | 1989 | |
University of California | Medical Degree | 1989 |
Institution | Focus | Year |
---|---|---|
Residency - Stanford University Hospital, Pediatric Hematology-Oncology; University Ca Sf Medical Center, Pediatrics | Not Specified |
Publication | Publisher | Title | Published |
---|---|---|---|
Other Publication | BRITISH JOURL OF HAEMATOLOGY | Development and validation of a single-cell network profiling assay | 2013 |
Other Publication | LEUKEMIA | Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome | 2013 |
Other Publication | PLOS ONE | AKT Sigling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab | 2013 |
Other Publication | BLOOD | Massive evolution of the immunoglobulin heavy chain locus | 2012 |
Other Publication | LEUKEMIA RESEARCH | Assessing sigling pathways associated with in vitro resistance to cytotoxic agents in AML | 2012 |
Other Publication | PLOS ONE | Circular Rs Are the Predomint Transcript Isoform from Hundreds of Human Genes in Diverse Cell Types | 2012 |
Other Publication | JOURL OF NEURO-OPHTHALMOLOGY | Dorsolateral Midbrain MRI Abnormalities | 2011 |
Other Publication | BRAIN INJURY | A pilot study of an online cognitive rehabilitation program for executive function skills | 2011 |
Other Publication | LANCET ONCOLOGY | Minimal residual disease-directed therapy for childhood acute myeloid leukaemia | 2010 |
Other Publication | PEDIATRIC BLOOD & CANCER | Phase I Study of Valspodar | 2010 |
Other Publication | BLOOD | Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding | 2010 |
Other Publication | PEDIATRIC BLOOD & CANCER | WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML | 2009 |
Other Publication | PEDIATRIC BLOOD & CANCER | Speeding the Flow Toward Persolized Therapy in Childhood Acute Leukemia | 2009 |
Other Publication | CANCER GENETICS AND CYTOGENETICS | Molecular inversion probes reveal patterns of 9p21 deletion | 2009 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Genomics of childhood leukemias: The virtue of complexity | 2008 |
Other Publication | PEDIATRIC AND DEVELOPMENTAL PATHOLOGY | Tissue microarrays from bone marrow aspirates for high | 2008 |
Other Publication | DM DISEASE-A-MONTH | Acute leukemia in children | 2008 |
Other Publication | BLOOD | The incidence and clinical significance of nucleophosmin mutations in childhood AML | 2007 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Differential gene expression patterns and interaction networks in BCR-ABL | 2007 |
Other Publication | CLINICAL CANCER RESEARCH | CpG island methylator phenotype and childhood leukemia | 2006 |
Other Publication | LEUKEMIA | Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is | 2006 |
Other Publication | BLOOD | Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission | 2006 |
Other Publication | Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu, | Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia | 2005 |
Other Publication | BLOOD | Gene expression profiles at diagnosis | 2004 |
Other Publication | Jourl of experimental therapeutics & oncology | Modulation of resistance to idarubicin by the cyclosporin PSC 833 | 2003 |
Other Publication | GENES CHROMOSOMES & CANCER | Preferential expression of a mutant allele of the amplified MDR1 | 2002 |
Other Publication | LEUKEMIA | Pharmacokinetic interactions of cyclosporine with etoposide | 2002 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2000 |
Other Publication | MOLECULAR PHARMACOLOGY | Loss of cyclosporin | 2000 |
Other Publication | JOURL OF BIOLOGICAL CHEMISTRY | Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype | 1997 |
Norman James Lacayo, MD has not yet indicated the hospitals that he is affiliated with.
Accepts New Patients: Yes
Norman James Lacayo, MD has not yet listed the medications that he commonly prescribes.
Norman James Lacayo, MD has not yet added any information about his practice's billing policies and payment options.